PT Jayamas Medica Industri Tbk (IDX: OMED)
181.00
+2.00 (1.12%)
Sep 10, 2024, 3:48 PM WIB
OMED Income Statement
Financials in millions IDR. Fiscal year is January - December.
Millions IDR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Revenue | 1,805,296 | 1,736,990 | 1,739,054 | 2,226,573 | 1,994,540 | 1,228,049 |
Revenue Growth (YoY) | 3.93% | -0.12% | -21.90% | 11.63% | 62.42% | - |
Cost of Revenue | 1,225,262 | 1,185,056 | 1,176,045 | 1,322,544 | 957,599 | 782,576 |
Gross Profit | 580,034 | 551,934 | 563,010 | 904,030 | 1,036,940 | 445,473 |
Selling, General & Admin | 255,159 | 250,002 | 198,309 | 168,243 | 186,715 | 149,961 |
Other Operating Expenses | 3,611 | 1,057 | -7,542 | 2,951 | 736.38 | 3,335 |
Operating Expenses | 258,682 | 251,059 | 190,767 | 171,194 | 187,451 | 153,295 |
Operating Income | 321,352 | 300,875 | 372,243 | 732,836 | 849,489 | 292,178 |
Interest Expense | -19,761 | -19,581 | -20,805 | -21,840 | -9,008 | -384.94 |
Interest & Investment Income | 51,770 | 43,520 | 14,371 | 16,909 | 14,945 | 10,157 |
Currency Exchange Gain (Loss) | 17,748 | 1,654 | 6,704 | 1,445 | 5,821 | 185.87 |
Other Non Operating Income (Expenses) | -397.11 | -341.03 | -403.98 | -328.64 | -149.77 | -146.62 |
EBT Excluding Unusual Items | 370,712 | 326,127 | 372,109 | 729,020 | 861,098 | 301,989 |
Gain (Loss) on Sale of Assets | -101.6 | 35.59 | 0.04 | 179.92 | 583.7 | 297.57 |
Pretax Income | 370,611 | 326,162 | 372,109 | 729,200 | 861,681 | 302,287 |
Income Tax Expense | 76,040 | 65,180 | 81,602 | 158,821 | 168,812 | 74,262 |
Earnings From Continuing Operations | 294,571 | 260,982 | 290,507 | 570,379 | 692,869 | 228,024 |
Minority Interest in Earnings | -1,874 | -1,622 | -4,725 | -7,687 | -7,359 | -1,816 |
Net Income | 292,696 | 259,360 | 285,782 | 562,692 | 685,510 | 226,208 |
Net Income to Common | 292,696 | 259,360 | 285,782 | 562,692 | 685,510 | 226,208 |
Net Income Growth | 7.67% | -9.25% | -49.21% | -17.92% | 203.04% | - |
Shares Outstanding (Basic) | 27,059 | 27,059 | 27,059 | 27,059 | 27,455 | 51,111 |
Shares Outstanding (Diluted) | 27,059 | 27,059 | 27,059 | 27,059 | 27,455 | 51,111 |
Shares Change (YoY) | -6.98% | - | - | -1.44% | -46.28% | - |
EPS (Basic) | 10.82 | 9.59 | 10.56 | 20.80 | 24.97 | 4.43 |
EPS (Diluted) | 10.82 | 9.59 | 10.56 | 20.80 | 24.97 | 4.43 |
EPS Growth | 15.75% | -9.25% | -49.21% | -16.72% | 464.16% | - |
Free Cash Flow | 283,516 | -22,031 | 17,549 | 422,386 | 228,771 | 160,224 |
Free Cash Flow Per Share | 10.48 | -0.81 | 0.65 | 15.61 | 8.33 | 3.13 |
Dividend Per Share | 2.880 | 6.050 | - | 10.870 | 17.000 | - |
Dividend Growth | -9.15% | - | - | -36.06% | - | - |
Gross Margin | 32.13% | 31.78% | 32.37% | 40.60% | 51.99% | 36.27% |
Operating Margin | 17.80% | 17.32% | 21.40% | 32.91% | 42.59% | 23.79% |
Profit Margin | 16.21% | 14.93% | 16.43% | 25.27% | 34.37% | 18.42% |
Free Cash Flow Margin | 15.70% | -1.27% | 1.01% | 18.97% | 11.47% | 13.05% |
EBITDA | 361,375 | 335,378 | 392,559 | 752,142 | 864,958 | 305,786 |
EBITDA Margin | 20.02% | 19.31% | 22.57% | 33.78% | 43.37% | 24.90% |
D&A For EBITDA | 40,023 | 34,504 | 20,317 | 19,307 | 15,469 | 13,608 |
EBIT | 321,352 | 300,875 | 372,243 | 732,836 | 849,489 | 292,178 |
EBIT Margin | 17.80% | 17.32% | 21.40% | 32.91% | 42.59% | 23.79% |
Effective Tax Rate | 20.52% | 19.98% | 21.93% | 21.78% | 19.59% | 24.57% |
Source: S&P Capital IQ. Standard template. Financial Sources.